In Vivo Gene Editing to Treat Monogenic Blood Disorders

Time: 9:00 am
day: Day Two

Details:

• Moving from traditional gene therapy to in vivo gene editing approaches
• Combining CRISPR/Cas9 with second generation factor VIII transgene
• Targeting the liver to treat hemophilia and beta-thalassemia

Speakers: